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Breast-conserving surgery including whole breast irradiation has long been a recommended
procedure for early breast cancer. However, conventionally fractionated radiotherapy
requires a lengthy hospitalisation or prolonged commuting to a hospital for radiotherapy.
In  recent years, hypofractionated radiotherapy has increasingly been used. This method
involves higher fraction doses (above 2 Gy) as compared to conventional radiotherapy, so the
total dose can be delivered in fewer fractions and in a shorter overall treatment time. This
review aims at presenting most important outcomes of four randomised studies comparing
conventional and hypofractionated radiotherapy schemes including a total of 7000 patients.
These studies have not shown apparent differences in treatment efﬁcacy, incidence of late
post-radiotherapy complications or cosmetic effects during a 5–10 year follow-up, but longer
observation is warranted to fully evaluate the safety of this method. Currently, major soci-
eties consider modestly hypofractionated radiotherapy schemes as a routine managementin  selected groups of patients undergoing breast-conserving surgery. However, this method
should be used cautiously in patients with lymph node metastases, big breasts, receiving
chemotherapy or trastuzumab, or those under 50 years of age.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
fore an effective method of eradicating subclinical disease,1.  Background
Breast-conserving surgery followed by whole breast irra-
diation is a standard treatment of early breast cancer.
Numerous randomised studies and their metaanalyses have
conﬁrmed this procedure to be as effective as modiﬁed radical
mastectomy.1–6 These studies used conventional fractionation
schemes with total dose of 45–50.4 Gy delivered to the whole
breast and fractionated doses of 1.8–2.0 Gy delivered with a 5
days per week schedule. Currently, an additional boost dose of
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10–20 Gy is commonly administered to the tumour bed, lead-
ing to further improvement of local control.7,8 Total duration
of a conventionally fractionated radiotherapy is 5–7 weeks.
The application of postoperative radiotherapy reduces by two-
thirds the risk of 10-year local recurrence, thus enhancing
the chance for breast conservation and increasing the rate of
10-year survival by 5%.6 Postoperative radiotherapy is there- Medical University of Gdan´sk, De˛binki 7, 80-952 Gdan´sk, Poland.
ensuring local control with acceptable risk of late normal
tissue reactions (lungs, heart). However, with conventional
fractionation, this modality requires a lengthy hospitalisation
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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Table 1 – Major patient characteristics in phase III studies of hypofractionated radiotherapy.
Trial (Ref.) Age ≥ 50 years (%) pT1-2 (%) pN0 (%) Chemotherapy used (%) High tumour grade (%)
RMH/GOC14 70 94 40 14 NR
OCOG15 75 100 100 11 19
START A16 77 Majority 69 35 28
START B17 79 Majority 74 22 23
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aOCOG, Ontario Clinical Oncology Group; RMH/GOC, Royal Marsden Ho
Radiotherapy; NR, not reported.
r commuting to a hospital for radiotherapy. This may cre-
te a major obstacle for patients with disabilities or those
ho  cannot rely on their families’ support. In the USA, for
nstance, an estimated 30% of women after breast-conserving
urgery do not receive radiotherapy.9 The probability of miss-
ng radiotherapy is higher with older patients and those living
arther away from radiotherapy centres.10–12 As a result, a part
f the patients qualiﬁed for breast-conserving treatment opt
or mastectomy. Long-lasting radiotherapy is also associated
ith higher costs and longer waiting lists.
Hypofractionation is a strategy allowing shortening the
ime of radiotherapy. The method involves higher fraction
oses (above 2 Gy) as compared to conventional radiother-
py, so the dose can be delivered in fewer fractions. With
uch schemes, the total dose is usually lowered. There are
adiobiological reasons justifying the use of hypofractiona-
ion in breast cancer. The ˛/  ˇ value for breast cancer has
een estimated at 4 Gy, whereas the ˛/  ˇ value for soft tissues
s approximately 3.5 Gy.13 Since breast cancer sensitivity to
adiotherapy is similar to that of healthy tissues responding
ith late reactions, high fraction doses may be more  efﬁ-
ient in destroying tumour cells. There are concerns, however,
hat higher fractions may also increase the frequency and
everity of late post-radiation reactions. Four large phase III
rials have been conducted to compare results of conventional
ersus hypofractionated radiotherapy following surgery for
arly breast cancer (Table 1). The purpose of this paper is to
resent these studies, their main outcomes and conclusions
or clinical practice.
. Hypofractionated  radiotherapy  protocols
n  breast  cancer
.1. Study  of  the  Royal  Marsden  Hospital  and
loucestershire  Oncology  Centre  (RMH/GOC)
he RMH/GOC study compared two schemes of hypofrac-
ionated radiotherapy: 42.9 Gy in 13 fractions and 39 Gy in
3 fractions versus conventional radiotherapy (50 Gy in 25
ractions).13,14 All the schemes were administered over 5 days.
 total of 1410 early breast patients treated with breast-
onserving surgery were included in this study. The rates of
0-year local recurrence in the groups receiving 50 Gy, 39 Gy
nd 42.9 Gy were 12.1%, 14.8% and 9.6%, respectively. The dif-
erence between the groups receiving 39 Gy and 42.9 Gy was
igniﬁcant (p = 0.027). The cosmetic outcome was evaluated
ased on photos and physical examination during annual con-
rol visits. The photos of both breasts were taken immediately
fter surgery, then before radiotherapy, annually over 5 yearsl/Gloucestershire Oncology Centre; START, Standardisation of Breast
and upon completion of the 10-year treatment. The photos
were evaluated independently by two male doctors and one
female nurse. The evaluators did not know patients’ identity or
treatment allocation. Breast changes were compared using a
three-level scale (no change/minimal change – 0; small change
– 2;  large change – 3) in reference to the appearance from
the photo taken after surgery. The photographic evaluation
showed that after 10 years any changes in breast appearance
in the groups that had received 50 Gy, 42.9 Gy and 39 Gy were
found in 35.4%, 42.3% and 27.4% of patients, respectively. The
difference in breast appearance between the groups receiving
50 Gy and 39 Gy was signiﬁcant (p = 0.01), whereas between the
groups receiving 50 Gy and 42.9 Gy it was borderline (p = 0.05).
After 10-year follow-up, the photographic evaluation showed
signiﬁcant changes in breast appearance in the groups admin-
istered 50 Gy, 42.9 Gy and 39 Gy in 5.6%, 10.1% and 3.4% of
patients, respectively. The differences between the groups
receiving 39 Gy and 42.9 Gy and between the groups receiving
50 Gy and 42.9 Gy were signiﬁcant (p = 0.01), whereas no sig-
niﬁcant differences were found between the groups receiving
50 Gy and 39 Gy (p = 0.18). A clinical assessment made 10 years
after radiotherapy showed signiﬁcant differences between
all studied groups (p < 0.001). The worst cosmetic effect was
observed in the group treated with 42.9 Gy, and the best one
in the group administered 39 Gy.
2.2.  Study  of  the  Ontario  Clinical  Oncology  Group
(OCOG)
The OCOG trial, including 1234 patients with early-stage
breast cancer who underwent breast-conserving surgery com-
pared a conventional radiation regimen (50 Gy given in 25
fractions over 35 days) with hypofractionated radiation sched-
ule (42.5 Gy in 16 fractions over 22 days).15 The 10-year rate
of local relapse was 6.7% in the standard radiotherapy group
versus 6.2% in the hypofractionated radiotherapy group. The
subgroup analysis showed that radiotherapy efﬁcacy was sim-
ilar in both groups regardless of age, tumour size, status
of oestrogen receptors and chemotherapy. The hypofraction-
ated radiotherapy scheme was less effective in patients with
poorly differentiated breast cancer. Within this group, the
10-year local recurrence in patients administered hypofrac-
tionated and conventional radiotherapy was 15.6% and 4.7%,
respectively (p = 0.01). A good and very good cosmetic result
at 10 years was observed in 69.8% and 71.3% of women
in both groups, respectively (the difference non-signiﬁcant).
After 10 years of follow-up, no signiﬁcant differences were
found between the groups in the distribution of causes of
death including cardiac deaths.
nd ra68  reports of practical oncology a
2.3.  The  study  of  the  UK  Standardisation  of  Breast
Radiotherapy  (START)  Trial  A  (START  A)
The START trial compared three schemes of postoperative
radiotherapy in patients with early breast cancer subjected
to breast-conserving surgery or mastectomy: 50 Gy in 25 frac-
tions, 41.6 Gy in 13 fractions and 39 Gy in 13 fractions.16 All
schemes were delivered over 5 weeks. A total of 2236 patients
were entered into the trial. The 5-year rate of local relapse in
the groups receiving 50 Gy, 41.6 Gy and 39 Gy was 3.2%, 3.2%
and 4.6%, respectively (p = 0.74, p = 0.40, for the comparisons
between 41.6 Gy with 50 Gy and 39 Gy with 50 Gy, respectively).
The 5-year probability of disease-free survival in the groups
receiving 50 Gy, 41.6 Gy and 39 Gy was 86%, 88% and 85%,
respectively, whereas the absolute 5-year survival was 89%
for all groups. Changes in breast appearance at 5 years that
were self-evaluated as moderate or large were comparable
in the groups receiving 50 Gy and 41.6 Gy, and signiﬁcantly
better with regard to skin appearance after 39 Gy than after
50 Gy (p = 0.004). The incidence of ischaemic heart disease,
rib fractures and symptomatic pulmonary ﬁbrosis during a
median follow-up of 5.1 years was low and similar for all the
groups.
2.4. The  study  of  the  UK  Standardisation  of  Breast
Radiotherapy  (START)  Trial  B  (START  B)
The START B trial compared conventional fractionated
radiotherapy (50 Gy in 25 fractions over 5 weeks) with a
hypofractionated radiotherapy regimen (40 Gy in 15 fractions
over 3 weeks).17 The study included 2215 women treated
with mastectomy or breast-conserving surgery for early-
stage breast cancer. The 5-year local recurrence rates in the
groups receiving 40 Gy and 50 Gy were 2.0% and 3.3%, respec-
tively (p = 0.21). The 5-year disease-free survival rates in the
groups receiving 50 Gy and 40 Gy were 86% and 89%, respec-
tively, whereas the 5-year overall survival rates were 89% and
92%, respectively. No signiﬁcant differences were found in
patient self-evaluated cosmetic effect, except for better skin
appearance after the dose of 40 Gy (p = 0.02). The incidence of
ischaemic heart disease, rib fractures and symptomatic pul-
monary ﬁbrosis during a median follow-up of 6 years was
low and similar for both groups. No cases of brachial plexus
damage were recorded in patients irradiated to the region of
supraclavicular fossa and/or axilla.
Table 2 – Radiotherapy parameters in phase III studies of hypof
Trial (Ref.) Energy Planning Central axi
homogenei
RMH/GOC14 6 MV 2D or 3D −5 to +7 
OCOG15 60Co, 4, 6 MV 2D −7 to +7 
START A16 6 MV 2D or 3D −5 to +5 
START B17 6 MV 2D or 3D −5 to +5 
OCOG, Ontario Clinical Oncology Group; RMH/GOC, Royal Marsden Hos
Breast Radiotherapy; 2D, two-dimensional; 3D, three-dimensional; SCV, s
megavoltage.diotherapy 1 7 ( 2 0 1 2 ) 66–70
2.5.  The  UK  FAST  trial
The FAST trial is a prospective randomised trial testing
two schemes of hypofractionated radiotherapy (28.5 Gy in 5
fractions and 30 Gy in 5 fractions over 5 weeks) versus con-
ventional radiotherapy regimen (50 Gy in 25 fractions over 5
weeks).18 This study included 900 patients with early breast
cancer who underwent conservation surgery. The ﬁrst anal-
ysis of the results after a median follow-up of 28 months
showed non-inferiority with respect to local control and cos-
metic outcome.19
3.  Discussion
Results of randomised trials comparing conventional and
modestly hypofractionated (13–16 fractions) radiotherapy
schemes including a total of 7000 patients have not shown
apparent differences in treatment efﬁcacy, incidence of late
post-radiotherapy complications or cosmetic effects during a
5–10 year follow-up. The Ontario study, due to its long follow-
up, provides a particularly strong evidence of non-inferiority
of this approach compared with conventionally fractionated
radiotherapy. This ﬁnding is also supported by the results
of the three large completed UK studies. The late outcomes
of radiotherapy including just 5 large fractions over 5 weeks
remain to be established. Yet there are still some uncertainties
about whether hypofractionated schemes can be safely imple-
mented as a routine practice in all patients with breast cancer.
Even though entry criteria for the above-mentioned studies
were relatively broad, most patients were over 50 years old,
had been treated with breast-conserving surgery for pT1–2N0
cancer and had not received irradiation to nodal ﬁelds or
chemotherapy. These studies used both 2D and 3D techniques
and a boost to the tumour bed was not always administered
or varied in dose (Table 2). Due to this selective assignment of
patients, it is not known whether hypofractionation is equally
effective and safe in patients with lymph node metastases,
big breasts, receiving chemotherapy or trastuzumab, or those
under 50 years of age.
Data from earlier observations show that radiotherapy-
related cardiovascular toxicity manifests only after 10 years
after treatment.20 There are concerns, therefore, that the
follow-up of 5–10 years may be too short to fully evaluate the
safety of hypofractionated radiotherapy for early breast can-
cer. A long-term follow-up is also required for a full efﬁcacy
assessment. For example, in the EORTC trial evaluating the
ractionated radiotherapy.
s dose
ty (%)
Boost (electrons) Nodal irradiation
14 Gy/7 fr (75%) SCV ± Ax (21%)
No No
10 Gy/5 fr (61%) SCV ± Ax (14%)
10 Gy/5 fr (31%) SCV ± Ax (7%)
pital/Gloucestershire Oncology Centre; START, Standardisation of
upraclavicular lymph nodes; Ax, axilla; fr, number of fractions; MV,
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2reports of practical oncology an
ole of boost dose in postoperative whole breast irradiation, 10-
ear results differed from those observed at 5 years.7,8 Indeed,
igher doses to a tumour bed were found to reduce the rate of
ocal relapse not only in younger patients (as observed already
fter 5 years) but also in the older age group. Therefore, some
oncerns have been raised that the 5-year follow-up in START
 and START B may be too short to fully evaluate treatment
fﬁcacy.
Based on the data from the above-presented randomised
tudies, the American Society for Radiation Oncology has
ssued recommendations for postoperative whole breast irra-
iation hypofractionated schemes.21 It was agreed that:
Evidence supports the equivalence of hypofractionated
hole breast irradiation with conventionally fractionated
hole breast irradiation for patients who meet all of these
riteria:
Age ≥ 50 years at diagnosis
 Pathologic stage T1-2
 Breast-conserving surgery
 No chemotherapy
 Dose heterogeneity within ±7% limits.
A group of British Columbia experts concluded that
ypofractionation should now be considered a new stan-
ard for radiation therapy after breast conserving surgery.22
he Expert Panel at the early breast treatment conference in
t. Gallen in 2011 also endorsed accelerated radiotherapy to
he whole breast following a breast-conserving surgery as an
cceptable procedure, but was divided about the use of this
pproach in the presence of extensive vascular invasion.23
In conclusion, modestly hypofractionated radiotherapy
n breast cancer is a valuable alternative to conventional
ractionated radiotherapy and existing randomised studies
onﬁrm its effectiveness and safety. The follow-up of 5–10
ears does not allow, however, the deﬁnite exclusion of a
ossibility of increased risk of late post-radiation reactions
ertaining mainly to the heart. These schemes should, there-
ore, be used with particular caution in young patients with
eft-sided tumours.
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